Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 23M | 18M | 0 | 33M |
| Gross Profit | -10M | 2M | 0 | 6M |
| Operating Income | -81M | -6M | -3M | -3M |
| EBITDA | -78M | -5M | -3M | -369K |
| Net Income | -101M | -7M | -3M | -3M |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$3.39
-8.38% today
1Y Change
-93.50%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Wellgistics Health, Inc. (WGRX) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $3.39 and down 93.5% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +28.7%, EPS growth of -1000.0%, a dividend yield of 0.0%. What stands out right now is revenue +28.7%, EPS -1000.0%, free cash flow -577.5% with operating margin -347.9% and ROIC -669.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines WGRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WGRX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
WGRX Max Drawdown
-96.35%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for WGRX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$32.8M
FY Net Income
-$2.7M
+5.2% YoY
Free Cash Flow
$0.0
+100.0% YoY
Revenue Growth
+28.7%
EPS Growth
-1000.0%
Gross Margin
-41.3%
Net Margin
-433.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 23M | 18M | 0 | 33M |
| Gross Profit | -10M | 2M | 0 | 6M |
| Operating Income | -81M | -6M | -3M | -3M |
| EBITDA | -78M | -5M | -3M | -369K |
| Net Income | -101M | -7M | -3M | -3M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash & Equivalents | 43K | 1M | 1K |
| Total Assets | 30M | 57M | 338K |
| Total Liabilities | 43M | 51M | 3M |
| Shareholder Equity | -12M | 7M | -3M |
| Total Debt | 25M | 25M | 700K |
| Net Debt | 25M | 24M | 699K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
0
+100.0% YoY
Capital Expenditures
0
Free Cash Flow
0
+100.0% YoY
Key ratios
Gross Margin
-41.3%
Operating Margin
-347.9%
Net Margin
-433.9%
ROE
141760.2%
Debt / Equity
-1.97x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.